All In Biotech

Drug Trial Radar · NCT07061925

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Apr 23, 2025

Primary completion

Nov 21, 2025

Study completion Nov 26, 2025

Sponsor

Lead sponsor
Korea Arlico Pharm. Co., LtdIndustry
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

Conditions

  • Acute Bronchitis

Interventions

  • ALC-2203-1Drug

    This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

  • ALC-2203-2Drug

    This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

  • ALC-2203-ACDrug

    This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.

  • PlacaboDrug

    This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Bronchitis Severity Score (BSS) at Day 7Time frame: Baseline (Day 0) to Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Konkuk University Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.